Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • Bone Marrow & Stem Cell Transplant
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • Bone Marrow & Stem Cell Transplant
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Updated Glioblastoma Data Demonstrated Median OS of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy

November 18, 2026

PIVOT-006 Ph 3 Registrational Trial shows RFS Improvement in Intermediate-Risk and High-Grade Ta NMIBC

November 18, 2026

68% high-grade RFS reported at 12 months in BCG-unresponsive NMIBC study of HIVEC® with mitomycin C

November 18, 2026

Positive Preliminary Ph 2 Topline Results Reported from the PIK-201 Trial of PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer

November 18, 2026

ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve NMIBC Randomized QUILT-2.005 Trial

November 18, 2026

Positive Updated Silevertinib Ph 2 Results Announced with FDA Feedback for Potential Registration path in 1L EGFR-NCM NSCLC

November 18, 2026

Quality of Life and Pain Outcomes Data from Ph 3 PANOVA-3 Trial of Tumor Treating Fields for Pancreatic Cancer Published

November 18, 2026

Updated interim results from U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial of Alpha DaRT for patients with recurrent GBM announced

November 18, 2026

Updated Clinical Data of Zocilurtatug Pelitecan (Zoci) in Previously Treated Extrapulmonary Neuroendocrine Carcinomas Presented

November 11, 2026

Preliminary Findings from the Investigator-Sponsored Ph 2a PICASSO Trial in Metastatic Melanoma Announced

November 11, 2026

Incremental Data and Analyses from Ph 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs Presented

November 11, 2026

Ph 2a PICASSO Trial of MaaT013 (Xervyteg®) + immune checkpoint inhibitors in selected melanoma patients met primary endpoint

November 11, 2026

Positive QoL Data for LYMPHIR® (denileukin diftitox-cxdl) in R/R Cutaneous T-Cell Lymphoma Presented

November 11, 2026

Ph 2 Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine

November 11, 2026

Subcutaneous RYBREVANT (amivantamab) demonstrates 77% ORR in 1L treatment of patients with certain types of advanced head and neck cancer

November 4, 2026

Updated data announced from Cohort 4 of Ph 1/2 GOBLET study of pelareorep + Tecentriq in 2L+ SCAC patients

November 4, 2026

Ph 3 LiGeR-HN1 trial of Petosemtamab + pembrolizumab versus pembrolizumab alone met both primary endpoints in PD-L1 positive HNSCC patients 

November 4, 2026

Positive Results from Ph 2 BELLA Trial of Lifyorli, Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer Reported

November 4, 2026

Statistically Significant OS/ORR Improvements reported with Petosemtamab Combo at First Interim Analysis in 1L R/M Patients with PD-L1+ Head and Neck Cancer

November 4, 2026

Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer

November 4, 2026

ELREXFIO demonstrated clinically meaningful & statistically significant PFS benefit for RRMM patients in Ph 3 MagnetisMM-32 trial

November 4, 2026

Updated results from Cohorts 1 and 2 of Ph 2 IOV-LUN-202 trial in previously treated non-squamous mNSCLC announced

November 4, 2026

Additional Positive Results of Combi-TED Ph 2 Trial with Tedopi® (OSE2101) in metastatic NSCLC Announced

November 4, 2026

Results from UNICORN Ph 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer Published in Nature Medicine

November 4, 2026

Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in PFS and OS in Patients with Platinum-Resistant Ovarian Cancer

October 27, 2026
Page1 Page2 Page3 … Page51

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.